Research programme: VEGF inhibitors - Interprotein
Latest Information Update: 08 Jan 2025
Price :
$50 *
At a glance
- Originator Interprotein Corporation
- Class Antibodies; Peptides; Small molecules
- Mechanism of Action Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Solid-tumours in Japan (PO)
- 26 Nov 2013 Early research is ongoing in Japan
- 21 Nov 2008 Early research in Solid tumours in Japan (PO)